Automating Directly Observed Therapy as a Platform Technology

简介：AI Cure Technologies LLC成立于2009年，旨在开发使用计算机视觉技术的自动化服药依从性监控解决方案。这个SBIR第二阶段将允许Ai Cure Technologies测试其旗舰产品AiView的准确性和有效性。SBIR第一阶段证明了AiView“平台在技术上是可行的，并能够确认给药。意义：服药依从性差是临床研究和临床实践的巨大负担。无法准确衡量或提高遵从性，这大大加剧了问题。临床试验取决于服用被测试药物的人。服药依从性的问题已经得到解决--依从性的决定因素正在研究中，新的监测方法正在开发--但还没有一种解决方案能够准确地确认实时用药依从性，同时又负担得起、灵活和讨人喜欢。产品：AI Cure Technologies将提供自动化DOT(直接观察疗法)软件平台AiView“，用于临床试验，在支持网络摄像头的智能手机或平板电脑上使用复杂的计算机视觉技术以视觉方式确认用药。AiView”将在没有人工监督的情况下以视觉方式跟踪和确认用药。长期目标：AiView“系统将以1/400的成本将复杂的计算机视觉技术与DOT的最佳属性相结合。自动化和标准化获取服药依从性的方式将帮助临床试验更好地定义受试者的依从性，并允许他们在不依从性的情况下立即干预。第二阶段假设：AiView”可用于准确测量和改善不同患者群体的用药依从性，并积极影响自我感知和临床结果。具体目标1：证明AiView“系统可以准确地测量和改善抑郁症和中风患者群体的用药依从性。具体目标2：证明AiView”系统可以改善AiView“干预组的自我知觉和改善临床结果预期结果：AiView”干预组的患者(抑郁症和中风)的服药依从率预计在统计学上显著高于药物计数组。

DESCRIPTION (provided by applicant): Introduction: Ai Cure Technologies LLC was established in 2009 to develop automated medication adherence monitoring solutions using computer vision technology. This SBIR Phase II will allow Ai Cure Technologies to test the accuracy and validity of its flagship product, AiView". The SBIR Phase I demonstrated that the AiView" platform was technically feasible and capable of confirming medication administration. Significance: Poor medication adherence is a huge burden on clinical research and clinical practice. The inability to accurately measure or improve adherence significantly compounds the problem. Clinical trials depend on people taking the drug being tested. The problem of medication adherence has been addressed - determinants of adherence are being studied and new monitoring methods developed - but no solution has been able to accurately confirm real-time medication adherence while also being affordable, flexible, and likable. The Product: Ai Cure Technologies will provide an automated DOT (Directly Observed Therapy) software platform, AiView", for use in clinical trials which uses sophisticated computer vision technology on webcam- enabled smart phones or tablets to visually confirm medication administration. AiView" will visually track and confirm medication administration without human supervision. Long-Term Goal: The AiView" system will combine sophisticated computer vision technology with the best attributes of DOT for 1/400th of the cost. Automating and standardizing the way medication adherence is captured will help clinical trials better define their subjects' rates of compliance and allow them to intervene immediately in case of non-compliance. Phase II hypothesis: AiView" can be used to accurately measure and improve medication adherence across different patient populations, and positively impact self-perception and clinical outcomes. Specific Aim #1: To demonstrate that the AiView" system can accurately measure and improve medication adherence in a depression and a stroke patient population. Specific Aim #2: To demonstrate that the AiView" system can improve self-perception and improve clinical outcomes in the AiView" intervention groups Expected Outcome: The patients in the AiView" intervention groups (depression and stroke) are expected to have statistically significant higher adherence rates than those in the pill counting groups.